AI
NBIX icon

Atria Investments’s Neurocrine Biosciences NBIX Stock Holding History

Atria Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13M Buy
12,667
+1,728
+16% +$256K 0.02% 726
2026
Q1 		$1.44M Buy
10,939
+443
+4% +$58.8K 0.02% 865
2025
Q4 		$1.49M Sell
10,496
-354
-3% -$51.3K 0.02% 863
2025
Q3 		$1.52M Buy
10,850
+176
+2% +$23.8K 0.02% 839
2025
Q2 		$1.34M Buy
10,674
+1,415
+15% +$162K 0.02% 903
2025
Q1 		$1.02M Buy
9,259
+4,164
+82% +$528K 0.01% 981
2024
Q4 		$695K Sell
5,095
-400
-7% -$49.5K 0.01% 1157
2024
Q3 		$633K Sell
5,495
-1,307
-19% -$179K 0.01% 1214
2024
Q2 		$936K Buy
+6,802
New +$933K 0.01% 974
2021
Q2 		– Sell
-10,710
Closed -$1.04M – 780
2021
Q1 		$1.04M Buy
+10,710
New +$1.12M 0.02% 690

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Atria Investments's NBIX Position: Q2 2026 in Review

Atria Investments increased its Neurocrine Biosciences (NBIX) stake by 16% in Q2 2026, buying an estimated $256K and bringing the position to 12,667 shares worth $2.13M. The position accounts for 0.02% of the portfolio, ranked #726.

Atria Investments first reported a position in NBIX in Q1 2021 and has held it in 10 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Atria Investments held 12,667 shares of Neurocrine Biosciences worth $2.13M as of Q2 2026.
  • Atria Investments bought 1,728 Neurocrine Biosciences shares in Q2 2026, an estimated $256K.
  • Neurocrine Biosciences made up 0.02% of Atria Investments's portfolio in Q2 2026, its #726 holding.
  • Atria Investments first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 10 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.